Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors
“Ironwood is committed to attracting board members who have an
owner-oriented mindset, business savvy, a strong interest in our
company, absolute integrity and great strategic judgment. We believe Amy
embodies each of these qualities, and that she will be a valuable
advisor as we seek to expand the reach and impact of our marketed
products, advance our internal pipeline, and identify opportunities to
access external innovation,” said
“Ironwood has successfully advanced an innovative product to market and established a strong commercial capability, which is driving revenue growth and pipeline development,” said Schulman. “This is how innovative biopharmaceutical companies are created, and it is an honor to join this Board as we help the terrific management team bring value for patients and shareholders.”
In addition to her roles at Lyndra, SQZ, and Polaris, Schulman is also a
senior lecturer at
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the expected benefits from Ms. Schulman's service on the Company's board, expanding the reach and impact of our marketed products, advancing our internal pipeline, identifying opportunities to access external innovation, and driving revenue growth and pipeline development. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to the effectiveness of commercialization efforts by us and our partners; preclinical and clinical development, manufacturing and formulation development; the risk that findings from our completed nonclinical and clinical studies may not be replicated in later studies; efficacy, safety and tolerability of linaclotide, lesinurad and our product candidates; decisions by regulatory authorities; the risk that we may never get sufficient patent protection for linaclotide and our product candidates or that we are not able to successfully protect such patents; developments in the intellectual property landscape; challenges from and rights of competitors or potential competitors; the risk that our planned investments do not have the anticipated effect on our company revenues, linaclotide, lesinurad or our product candidates; and the risks listed under the heading "Risk Factors" and elsewhere in Ironwood's Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, and in our subsequent SEC filings. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and Ironwood undertakes no obligation to update these forward-looking statements.
Ironwood Pharmaceuticals, Inc.
|"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Ironwood Pharmaceuticals's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.|
|INVESTOR RELATIONS CONTACT|